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Abstract
Background: Dipeptidyl peptidase-4 inhibitors are a class of oral hypoglycemic drugs and are used widely to treat
type 2 diabetes mellitus in many countries. Adverse effects include nasopharyngitis, headache, elevated serum
pancreatic enzymes, and gastrointestinal symptoms. In addition, a few cases of interstitial pneumonia associated
with their use have been reported in the Japanese literature. Here we describe a patient who developed
drug-induced acute lung injury shortly after the administration of the dipeptidyl peptidase-4 inhibitor vildagliptin.
Case presentation: A 38-year-old Japanese woman with diabetes mellitus developed acute respiratory failure 1 day
after administration of vildagliptin. Chest computed tomography revealed nonsegmental ground-glass opacities in
her lungs. There was no evidence of bacterial pneumonia or any other cause of her respiratory manifestations. After
discontinuation of vildagliptin, she recovered fully from her respiratory disorder. She received insulin therapy for her
diabetes mellitus, and her subsequent clinical course has been uneventful.
Conclusions: The period of drug exposure in previously reported cases of patients with drug-induced interstitial
pneumonia caused by dipeptidyl peptidase-4 inhibitor varied from several days to over 6 months. In the present case,
our patient developed interstitial pneumonia only 1 day after the administration of vildagliptin. The precise mechanism
of her vildagliptin-induced lung injury remains uncertain, but physicians should consider that dipeptidyl peptidase-4
inhibitor-induced lung injury, although rare, may appear acutely, even within days after administration of this drug.
Keywords: Dipeptidyl peptidase-4 inhibitor, Acute respiratory failure, Ground-glass opacity, Elevated pancreatic
enzyme, Diabetes mellitus, Human leukocyte antigen, Leukocyte migration test
Background
Dipeptidyl peptidase-4 (DPP-4) inhibitors, also called
gliptins, are a relatively new class of oral hypoglycemic
drugs with proven efficacy, tolerability, and safety [1, 2].
They are used widely to treat type 2 diabetes mellitus in
many countries. Adverse effects include nasopharyngitis,
headache, elevated serum pancreatic enzymes, gastro-
intestinal symptoms, and infrequent urticaria, angio-
edema, and hypersensitivity reactions. Overall, there
have been few reports on drug-induced lung injury
caused by DPP-4 inhibitors. However, several cases of
interstitial pneumonia (IP) associated with the use of
DPP-4 inhibitors have been reported in the medical
literature in Japanese [3–5].
Here we report a case of acute lung injury that
occurred shortly after the administration of a DPP-4
inhibitor, vildagliptin.
Case presentation
A 38-year-old Japanese woman was admitted to our hos-
pital because of coma after several hours of dyspnea and
hyperpnea. Her medical and family histories were unre-
markable. She had smoked 10 cigarettes per day for 18
years (9 pack years of tobacco smoking). She developed
thirst and polyuria 2 months before admission. The day
before admission, she visited a local clinic because of
persistent thirst, polyuria, and a 10-kg body weight loss
over the past 2 months. Her height, body weight, and
body temperature were 158 cm, 51 kg, and 36.8 °C,
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respectively. Blood chemistry showed a high fasting
plasma glucose level of 15.2 mmol/L, glycated hemoglobin
(HbA1c) of 9.8 %, and a normal white blood cell (WBC)
count of 5600/μL. A urine analysis was not performed.
She was diagnosed as having diabetes mellitus and
prescribed a DPP-4 inhibitor, vildagliptin, at 100 mg/day
(50 mg in the morning and 50 mg in the evening), which
she started taking that evening. In the midmorning of the
day of admission, she complained of nausea and vomiting;
by the evening, she had developed dyspnea and hyperpnea
without sputum.
On admission, she was comatose and breathing deeply
(24 breaths/minute). Her body weight, body temperature,
blood pressure, and heart rate were 49 kg, 35.7 °C, 91/54
mmHg, and 123 beats/minute, respectively. Her oral cav-
ity and skin were dry. No eruption, wheezing, chest rales,
or heart murmurs were detected; however, the breath
sounds in the lower lobes of her lungs were decreased.
Arterial blood gas analysis showed severe metabolic acid-
osis and a decreased partial oxygen pressure with impaired
pulmonary diffusion (Table 1). Blood chemistry revealed a
high WBC count, hyperglycemia, and ketonemia. Serum
creatinine, potassium, lactate dehydrogenase (LDH), and
C-reactive protein (CRP) were high. In addition, her
serum levels of pancreatic enzymes, such as amylase,
lipase, trypsin, and phospholipase A2, were high. A
chest X-ray showed abnormal shadows in the lower
lobes of her lungs (Fig. 1a). Computed tomography
(CT) showed ground-glass opacities in the lower lobes
of her lungs (Fig. 1c); no abnormality in her liver,
pancreas, or kidneys was detected. Blood culture and
urinary antigens of Streptococcus pneumoniae and
Legionella pneumophila were both negative. Her
serum β-D-glucan levels were normal. She tested
negative for anti-Mycoplasma pneumoniae antibody,
anti-Trichosporon asahii antibody, anti-nuclear anti-
body, and rheumatoid factor.
She was diagnosed as having diabetic ketoacidosis
(DKA) and acute renal failure and received intravenous
saline and insulin. Her pulmonary problems were ini-
tially treated with a course of empiric antibiotic therapy
with 0.75 g/day of intravenous meropenem and oxygen
inhalation.
The next day, she regained consciousness and was no
longer dyspneic. Her body temperature (36.8 °C), blood
pressure (112/74 mmHg), respiration rate (18 breaths/
minute), arterial pH (7.37), and partial oxygen pres-
sure (86.3 mmHg) had normalized without the need
for oxygen inhalation. Her plasma glucose had fallen
to 13.9 mmol/L, and her electrolytes were normal.
She began subcutaneous insulin injection therapy for
her diabetes mellitus on day 3 and did not resume taking
vildagliptin. Blood chemistry findings on day 5 were: a
WBC count of 4050/μL, serum CRP 0.33 mg/dL, LDH
Table 1 Laboratory findings at the time of admission in July 2013
Hematology
Red blood cells 510×104/μL (427–571)
Hemoglobin 15.2 g/dL (12.4–17.2)
Hematocrit 45.3 % (38.7–50.3)
White blood cells 28,840/μL (4000–9000)
Neutrophils 89.2 % (36.0–71.0)
Eosinophils 0.0 % (<11.0)
Basophils 0.2 % (<1.5)
Monocytes 6.8 % (<10.0)
Lymphocytes 3.9 % (20.0–50.0)
Platelets 30.9×104/μL (12.0–30.0)
Chemistry
Casual plasma glucose 49.8 mmol/L (3.9–7.8)
HbA1c 10.2 % (4.6–6.2)
Acetoacetate 1970 μmol/L (<55)
3-Hydroxybutyrate 5335 μmol/L (<85)
Total protein 7.0 g/dL (6.7–8.3)
Albumin 4.3 g/dL (3.8–5.3)
Aspartate aminotransferase 17 IU/L (13–33)
Alanine aminotransferase 19 IU/L (6–27)
Lactate dehydrogenase 262 IU/L (105–215)
Alkaline phosphatase 336 IU/L (115–359)
Amylase 124 IU/L (41–112)
Lipase 138 U/L (5–35)
Trypsin 995 ng/mL (100–550)
Phospholipase A2 5160 ng/dL (130–400)
Elastase-1 142 ng/dL (0–300)
Urea nitrogen 25.9 mg/dL (8.0–22.0)
Creatinine 1.57 mg/dL (0.4–0.7)
Sodium 125 mmol/L (137–147)
Potassium 7.1 mmol/L (3.5–4.7)
Chloride 98 mmol/L (98–108)
C-reactive protein 2.14 mg/dL (<0.30)
KL-6 195 U/mL (<490)
Arterial blood gas analysis under room air
pH 6.886 (7.35–7.45)
Partial carbon dioxide pressure 9.0 mmHg (32–48)
Partial oxygen pressure 83.1 mmHg (83–108)
Bicarbonate 1.6 mmol/L (21–28)
Saturation of arterial oxygen 94.3 % (95–99)
Alveolar-arterial oxygen difference 55.9 mmHg (5–10)
The reference range for each parameter is shown in parentheses.
HbA1c glycated hemoglobin, KL-6 sialylated carbohydrate antigen Krebs von
den Lungen-6
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222 IU/L, and creatinine 0.68 mg/dL. Because her re-
spiratory problems resolved, the meropenem was dis-
continued that day. Her serum CRP (0.09 mg/dL) and
LDH (177 IU/L) levels normalized on day 10. A chest
X-ray showed improvements in the reticular shadows
(Fig. 1b). Chest CT performed on day 19 found fewer
ground-glass opacities (Fig. 1d). A paired serum anti-
viral antibody test detected no elevation in antibody
titers to respiratory syncytial virus, parainfluenza virus
1 to 3, influenza virus A and B, adenovirus, Epstein–
Barr virus, human herpes virus, cytomegalovirus, or
herpes simplex virus.
Her serum C-peptide levels were low (<0.2 ng/mL)
before and after intravenous glucagon load on day 7 of
admission. She tested negative for glutamic acid decarb-
oxylase antibody (<1.5 U/mL) but positive for insulinoma-
associated antigen 2 autoantibody (3.1 U/mL; reference
range, <0.4 U/mL). These findings indicated a diagnosis of
type 1 diabetes mellitus (T1D). Human leukocyte antigen
(HLA) typing showed A*11:01/31:01, B*39:02/54:01, and
C*01:02/07:02 class I genes and DRB1*04:05/13:02,
DQB1*04:01/06:04, DQA1*01:02/03:03, and DPB1*04:01/
05:01 class II genes.
Serum levels of amylase (234 IU/L), lipase (201 U/L),
trypsin (2460 ng/mL), phospholipase A2 (1270 ng/dL),
and elastase-1 (1252 ng/dL) remained high on day 10,
but she had no abdominal pain and ultrasonography de-
tected no abnormality in her pancreas. All of these pan-
creatic enzymes (42 IU/L, 24 U/L, 299 ng/mL, 330 ng/
dL, and 142 ng/dL, respectively) normalized on day 28
of admission.
To examine the possible association of vildagliptin ad-
ministration with her elevated pancreatic enzymes and
acute lung injury, a cell-mediated immunity assessment
was performed. Vildagliptin yielded negative results in a
drug-induced lymphocyte stimulation test (DLST; stimu-
lation index 1.1, reference range <1.6) but positive re-
sults in a leukocyte migration test (LMT; migration
index 1.6, reference range 0.6 to 1.4).
After participating in a self-management diabetes mel-
litus education program, she was discharged on day 32.
She continued insulin therapy in the out-patient clinic of
our hospital, and her subsequent clinical course has
been uneventful.
Discussion
A Japanese woman with newly diagnosed diabetes melli-
tus began treatment with vildagliptin. The next day, she
was admitted to our hospital because of acute respira-
tory failure with abnormal lung shadows in a diabetic
Fig. 1 Radiologic findings. A chest X-ray performed on admission with the patient in the supine position showed a nodule-like shadow in the lower
lobe of her right lung and reticular shadows in the lower lobes of both lungs (a). A chest X-ray performed on day 10 after admission with the patient
in the sitting position showed improvements in the right nodular shadow and reticular shadows of the lower lobes of both lungs (b). Chest computed
tomography performed on admission showed subpleural-predominant, nonsegmental ground-glass opacities in the lower lobes of both lungs (c).
Chest computed tomography performed on day 19 after admission showed improvements in the ground-glass opacities in both lungs (d)
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coma. She regained her consciousness after correction of
DKA. Because her diabetes mellitus turned out to be
T1D, she received subcutaneous insulin injection ther-
apy and did not resume vildagliptin. Her pulmonary
problems resolved within weeks.
A chest CT performed at the time of admission re-
vealed bilateral, nonsegmental ground-glass opacities
in the lower lobes of her lungs (Fig. 1c). Although
her respiratory disorder resolved during a course of
empirical antibiotic therapy, there was no evidence of
bacterial pneumonia. In addition, there was no clin-
ical evidence of any other cause of her respiratory
manifestations, such as connective tissue diseases,
hypersensitivity pneumonitis secondary to inhaled or-
ganic dusts, fungal or viral infection, or hemodynamic
disturbances. She had no medication history over the
past few months other than 1 day of vildagliptin use.
Thus, on the basis of the clinical course and imaging
findings, she probably exhibited drug-induced IP
[6–8] caused by vildagliptin which she had taken the
previous day.
Assessment of cell-mediated immunity using DLST or
LMT is a method to confirm the diagnosis of drug-
induced disease by detecting drug-sensitized lympho-
cytes. A study of Japanese patients has shown that the
sensitivity of LMT for drug allergies including pulmon-
ary disorders was higher (approximately 60 %) than that
of DLST (approximately 20 %), while the specificity of
both tests is >90 % [9]. In the present case, our patient
showed a negative DLST but a positive LMT for vilda-
gliptin. Although these tests do not have a definite role
in the diagnosis of drug-induced lung injury [10], the
positive LMT in our patient supported the diagnosis of
vildagliptin-induced IP.
The period of drug exposure in previously reported
cases of patients with DPP-4 inhibitor-induced lung in-
jury varied from 4 days to 9 months [3–5]. In the
present case, our patient developed vildagliptin-induced
IP with a drug exposure time of only 1 day. The precise
mechanism of her vildagliptin-induced lung injury re-
mains uncertain, but physicians should consider that
drug-induced lung injury caused by DPP-4 inhibitor,
although rare, can appear acutely even within days after
the administration of this drug.
T1D is characterized by the destruction of pancre-
atic beta cells and insulin-deficient hyperglycemia
[11]. The rate of beta-cell destruction is variable from
patient to patient and depending on the manner of
onset and progression, T1D is classified as fulminant,
acute-onset, or slowly progressive in Japan. Our pa-
tient developed insulin-deficient hyperglycemia and
DKA following 2 months of hyperglycemic symptoms
and therefore met the diagnostic criteria for acute-
onset T1D [12]. The presence of the class II HLA-
DRB1*04:05-DQB1*04:01 haplotype is consistent with
her diagnosis of T1D.
She presented with elevated serum pancreatic enzymes
without abdominal pain or morphological changes in her
pancreas during the weeks after admission. Such elevated
pancreatic enzymes are usually observed at the onset of
fulminant T1D [13], which is distinguished from acute-
onset T1D by the abrupt occurrence of insulin deficiency
and DKA within days and the absence of islet-related auto-
antibodies. She developed acute-onset T1D in the presence
of islet-related autoantibodies and never experienced
fulminant T1D. Therefore, her elevated serum pancreatic
enzymes were probably induced by vildagliptin [1, 6].
Following hyperglycemic symptoms, including thirst,
polyuria, and a 10-kg body weight loss over 2
months, she dramatically fell critically ill within 24
hours before admission for acute respiratory failure
and severe DKA and fulfilled the criteria for systemic
inflammatory response syndrome [14]. DKA is a
serious acute metabolic complication of diabetes mel-
litus characterized by uncontrolled hyperglycemia,
metabolic acidosis, and increased total body ketone
concentration. Hyperglycemia in patients with DKA is
known to be associated with a severe inflammatory state
characterized by elevated proinflammatory cytokines [15].
Of importance, respiratory failure aggravates the course of
DKA [16]. These findings suggest that in the present case,
the development of vildagliptin-induced acute lung injury
under conditions of insulin-deficient hyperglycemia likely
precipitated and aggravated DKA and resulted in the
acute crisis.
Drug-induced IP can occur in patients taking
methotrexate, which is an antimetabolite and antifo-
late drug used to treat cancer and autoimmune dis-
ease [17]. Japanese patients with rheumatoid arthritis
are known to be more susceptible to methotrexate-
induced IP than are other ethnic groups. A genetic
study of Japanese patients suggested the presence of
HLA-A*31:01 as a predisposing factor for drug-
induced IP caused by methotrexate and possibly other
drugs [18]. Our patient had never taken methotrexate
and did not have rheumatoid arthritis, but there may
have been an association between her HLA-A*31:01
and vildagliptin-induced IP.
Conclusions
We described a Japanese patient with diabetes melli-
tus who developed drug-induced acute lung injury
and elevated serum pancreatic enzymes caused by
vildagliptin, both of which were reversible after dis-
continuation of the drug. The present case suggests
that drug-induced lung injury caused by a DPP-4
inhibitor may appear acutely even within days after
administration.
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